立体定向MR引导自适应放疗用于高危肺肿瘤的临床结局
本研究纳入50例高危肺肿瘤患者(54个肿瘤),因肿瘤位置、运动或肺合并症导致治疗困难而接受立体定向MR引导自适应放疗(SMART)。中位随访21.7个月,12个月局部控制率为95.6%,总生存率88.0%,无病生存率63.6%,≥3级毒性发生率为8%,无4-5级毒性。结论认为SMART在高危肺肿瘤中可获得较低的髙级别毒性和令人鼓舞的早期局部控制。
要点
- SMART在高危肺肿瘤中12个月局部控制率达95.6%。
- ≥3级毒性发生率为8%,未观察到4级或5级毒性。
- 每日自适应计划使93%肿瘤达到BED≥100 Gy(95% PTV)。
核心结论
- MR引导的SABR在高危肺肿瘤队列中导致低级别髙级毒性发生率和令人鼓舞的早期局部控制。
- 需要进一步研究以识别最可能从SMART方法中获益的患者。
研究设计与样本
- 前瞻性单臂研究,纳入2016年至2018年间连续50例患者(54个肺肿瘤),其中原发性肺癌29例、肺转移21例。
- eligible患者具有易致毒性的危险因素,包括中央型肿瘤位置(n=30)、既往胸部放疗(n=17)和间质性肺病(n=7)。
- 治疗采用每日17秒屏气MR扫描定位,基于当日解剖结构进行在线计划自适应,并在连续MR引导下于重复屏气中实施门控SABR。
主要发现
- 除1例患者外,所有患者均完成计划的SMART疗程。
- 通过每日计划自适应,50个肿瘤(93%)的95%计划靶区体积达到生物有效剂量≥100 Gy。
- 中位随访21.7个月(95%CI 19.9-28.1),12个月局部控制率、总生存率和无病生存率分别为95.6%、88.0%和63.6%。
- 4例患者出现局部失败:2例为复发性肺癌再程放疗后,2例为结直肠转移瘤患者。
- 任何≥2级和≥3级毒性总发生率分别为30%和8%;最常见的≥2级毒性为放射性肺炎(12%)和胸壁疼痛(8%),未观察到4级或5级毒性。
临床怎么用
- 对于因中央型位置、既往胸部放疗或间质性肺病等高危因素导致治疗困难的肺肿瘤患者,可考虑采用SMART以实现每日自适应和门控照射。
局限性
- 样本量较小(50例患者,54个肿瘤),且为单臂研究设计,未设对照组。
- 随访时间较短(中位21.7个月),早期局部控制结果需更长期随访验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Magnetic resonance (MR)-guided SABR was performed for patients with lung tumors in whom treatment delivery was challenging owing to tumor location, motion, or pulmonary comorbidity. Because stereotactic MR-guided adaptive radiation therapy (SMART) is a novel approach, we studied clinical outcomes in these high-risk lung tumors. METHODS AND MATERIALS: Fifty consecutive patients (54 lung tumors) underwent SMART between 2016 and 2018 for either a primary lung cancer (29 patients) or for lung metastases (21 patients). Eligible patients had risk factors that could predispose them to toxicity, including a central tumor location (n = 30), previous thoracic radiation therapy (n = 17), and interstitial lung disease (n = 7). A daily 17-second breath-hold MR scan was acquired in treatment position, and on-table plan adaptation was performed using the anatomy of the day. Gated SABR was delivered during repeated breath-holds under continuous MR guidance. RESULTS: All but 1 patient completed the planned SMART schedule. With daily plan adaptation, a biologically effective dose ≥100 Gy to 95% of the planning target volume was delivered in 50 tumors (93%). Median follow-up was 21.7 months (95% confidence interval, 19.9-28.1). Local control and overall and disease-free survival rates at 12 months were 95.6%, 88.0%, and 63.6%, respectively. Local failures developed in 4 patients: in 2 after reirradiation for a recurrent lung cancer and in 2 patients with a colorectal metastasis. Overall rates of any grade ≥2 and ≥3 toxicity were 30% and 8%, respectively. Commonest toxicities were grade ≥2 radiation pneumonitis (12%) and chest wall pain (8%). No grade 4 or 5 toxicities were observed. CONCLUSIONS: Use of MR-guided SABR resulted in low rates of high-grade toxicity and encouraging early local control in a cohort of high-risk lung tumors. Additional studies are needed to identify patients who are most likely to benefit from the SMART approach.
引用
- Finazzi T, Haasbeek CJA, Spoelstra FOB, et al. Clinical Outcomes of Stereotactic MR-Guided Adaptive Radiation Therapy for High-Risk Lung Tumors. Int J Radiat Oncol Biol Phys. 2020. PMID: 32105742. doi:10.1016/j.ijrobp.2020.02.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。